Jonathan Kay to Biosimilar Pharmaceuticals
This is a "connection" page, showing publications Jonathan Kay has written about Biosimilar Pharmaceuticals.
Connection Strength
13.275
-
Kay J, Cross RK, Feldman SR, Park Y, Hanauer SB. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 02; 41(2):509-533.
Score: 0.848
-
Kay J. Multiple switching studies and interchangeability of biosimilars. Lancet Rheumatol. 2023 Sep; 5(9):e499-e501.
Score: 0.829
-
Kay J, Bock AE, Rehman M, Zhang W, Zhang M, Iikuni N, Alvarez DF. Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis. RMD Open. 2022 09; 8(2).
Score: 0.775
-
Yu KS, Jang IJ, Lim HS, Hong JH, Kim MG, Park MK, Cho DY, Park MS, Chung JY, Ghim JL, Lee S, Yoon SK, Kwon IS, Lee SJ, Kim SH, Bae YJ, Cha JB, Furst DE, Keystone E, Kay J. Pharmacokinetic equivalence of CT-P17 to high-concentration (100?mg/ml) reference adalimumab: A randomized phase I study in healthy subjects. Clin Transl Sci. 2021 07; 14(4):1280-1291.
Score: 0.699
-
Kay J, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, Jeka S, Zielinska A, Trefler J, Bartnicka-Maslowska K, Krajewska-Wlodarczyk M, Klimiuk PA, Lee SJ, Bae YJ, Yang GE, Yoo JK, Furst DE, Keystone E. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Res Ther. 2021 02 05; 23(1):51.
Score: 0.695
-
Alvarez DF, Wolbink G, Cronenberger C, Orazem J, Kay J. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? BioDrugs. 2020 Dec; 34(6):723-732.
Score: 0.687
-
Baker JF, Leonard CE, Lo Re V, Weisman MH, George MD, Kay J. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis Rheumatol. 2020 07; 72(7):1067-1071.
Score: 0.660
-
Kay J. Overcoming barriers to biosimilars in inflammatory arthritis. Nat Rev Rheumatol. 2020 Feb; 16(2):65-66.
Score: 0.648
-
Kay J. Are There Benefits and Risks to Biosimilars from a Patient Perspective? Rheum Dis Clin North Am. 2019 08; 45(3):465-476.
Score: 0.618
-
Kay J. A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extension. J Intern Med. 2019 06; 285(6):693-695.
Score: 0.614
-
Kay J, D?rner T, Emery P, Kvien TK, Breedveld FC. Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar. Ann Rheum Dis. 2020 04; 79(4):e44.
Score: 0.603
-
Kay J, Schoels MM, D?rner T, Emery P, Kvien TK, Smolen JS, Breedveld FC. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018 02; 77(2):165-174.
Score: 0.548
-
Kay J, Winthrop KL. Pharmacotherapy: Biosimilar switching - "To set a form upon desired change". Nat Rev Rheumatol. 2017 07; 13(7):391-392.
Score: 0.539
-
Cohen S, Kay J. Biosimilars: implications for rheumatoid arthritis therapy. Curr Opin Rheumatol. 2017 05; 29(3):260-268.
Score: 0.536
-
Braun J, Kay J. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2017 Mar; 16(3):289-302.
Score: 0.524
-
Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis. 2017 01; 76(1):4-6.
Score: 0.511
-
Kay J. Editorial: Biosimilars: New or D?j? Vu? Arthritis Rheumatol. 2016 05; 68(5):1049-52.
Score: 0.500
-
Lambert J, Wyand M, Lassen C, Shneyer L, Thomson E, Knight A, Willers J, Kay J. Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Int J Clin Pharmacol Ther. 2016 Apr; 54(4):315-22.
Score: 0.497
-
D?rner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015 Dec; 11(12):713-24.
Score: 0.476
-
Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology--"O brave new world". Nat Rev Rheumatol. 2012 06 05; 8(7):430-6.
Score: 0.381
-
Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, Eduru SK, Buschke S, Lang B, Liesenfeld KH, Schaible J, McCabe D. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728.
Score: 0.193
-
Furst DE, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, Jeka S, Zielinska A, Trefler J, Bartnicka-Maslowska K, Krajewska-Wlodarczyk M, Klimiuk PA, Lee SJ, Kim SH, Bae YJ, Yang GE, Yoo JK, Kay J, Keystone E. Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Rheumatology (Oxford). 2022 04 11; 61(4):1385-1395.
Score: 0.189
-
Davidson A, Brimhall D, Kay J, Keystone E, Lee SJ, Kim SH, Bae YJ, Choi EJ, Furst DE. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40?mg/0.4?mL) by autoinjector and prefilled syringe in healthy subjects. Br J Clin Pharmacol. 2021 11; 87(11):4323-4333.
Score: 0.177
-
Curtis JR, Xie F, Kay J, Kallich JD. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Arthritis Res Ther. 2019 12 12; 21(1):285.
Score: 0.161
-
Bridges SL, White DW, Worthing AB, Gravallese EM, O'Dell JR, Nola K, Kay J, Cohen SB. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Arthritis Rheumatol. 2018 03; 70(3):334-344.
Score: 0.141
-
D?rner T, Strand V, Cornes P, Gon?alves J, Gul?csi L, Kay J, Kvien TK, Smolen J, Tanaka Y, Burmester GR. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016 06; 75(6):974-82.
Score: 0.124
-
Vital EM, Kay J, Emery P. Rituximab biosimilars. Expert Opin Biol Ther. 2013 Jul; 13(7):1049-62.
Score: 0.101